EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRPV1 Blocker, Peptide HCRG21 from Sea Anemone Heteractis magnifica, Exhibits Effectiveness in Psoriasis and Dermatitis in In Vivo Models

Anna Klimovich iD, Aleksandra Kvetkina iD, Yulia Deryavko, Nadezhda Priymenko, Daria Popkova iD, Evgenia Bystritskaya, Marina Isaeva iD, Irina Gladkikh, Oksana Sintsova iD, Elena Leychenko iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262110644 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anna Klimovich und 9 weiteren Autor:innen. Beteiligte Einrichtung: G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia. Hauptthemen laut MEDLINE: TRPV Cation Channels, Psoriasis, Sea Anemones, Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FEFU development program within the framework of the university's participation in the «Priority 2030» strategic academic leadership program», FEFU development program within the framework of the university’s participation in the “Priority 2030” strategic academic leadership program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis and allergic contact dermatitis (ACD) are the most common chronic inflammatory diseases, which are accompanied by epithelial alterations and a T cell-mediated immunopathology. In this study, we investigated the anti-ACD and anti-psoriasis effects of sea anemone Heteractis magnifica peptide HCRG21, a blocker of the TRPV1 channel, in 2,4-dinitrofluorobenzene (DNFB)- and imiquimod (IMQ)-induced mouse models, respectively. We found that topical application of 0.005–0.1% HCRG21 gels normalized hematological and immunological blood parameters in mice, significantly reduced the severity of ACD- and psoriasiform-like skin lesions, and increased the rate of tissue repair. The use of 0.005 and 0.05% HCRG21 gels decreased the production of IL-23-A and macrophage-derived chemokine (MDC) proteins in blood plasma, reduced the expression of Tnf, Il1β, Il6, Il23a, and Il17a genes, but increased the levels of the Il10 gene in scabs and/or blood of IMQ-treated mice. On the other hand, topical application of 0.05 and 0.1% HCRG21 reduced the expression of Il6 and Il23a in the DNFB-treated mice’s blood and it had no significant effects on TNF-α and IL-1β production. Thus, HCRG21 has the potential to be a treatment for psoriasis and dermatitis due to its potent anti-inflammatory properties. This effect is achieved by reducing pro-inflammatory cytokines associated with TRPV1 and normalizing immune cell levels in the bloodstream. This, in turn, leads to a decrease in clinical symptoms and an improvement in skin healing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPV Cation ChannelsPsoriasisSea AnemonesPeptidesDermatitisAnimalsMiceDisease Models, AnimalCytokinesImiquimodDinitrofluorobenzeneMaleFemale

Stichwörter der Autor:innen

Kunitz-type peptideTRPV1 channelallergic contact dermatitiscytokinesimiquimod-induced modelpsoriasisskin inflammation

Substanzen

TRPV Cation ChannelsCytokinesTRPV1 protein, mouseImiquimodPeptidesDinitrofluorobenzene

Autor:innen und Institutionen

  • G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia.
  • Advance Engineering School "Institute of Biotechnology, Bioengineering and Food Systems", Far Eastern Federal University, 690920 Vladivostok, Russia.

ORCID-Profile: Anna Klimovich, Aleksandra Kvetkina, Daria Popkova, Marina Isaeva, Oksana Sintsova, Elena Leychenko

Förderung

  • FEFU development program within the framework of the university's participation in the «Priority 2030» strategic academic leadership program»
  • FEFU development program within the framework of the university’s participation in the “Priority 2030” strategic academic leadership program

Zitieren

APA

Klimovich, A., Kvetkina, A., Deryavko, Y., Priymenko, N., Popkova, D., Bystritskaya, E., Isaeva, M., Gladkikh, I., Sintsova, O., & Leychenko, E. (2025). TRPV1 Blocker, Peptide HCRG21 from Sea Anemone Heteractis magnifica, Exhibits Effectiveness in Psoriasis and Dermatitis in In Vivo Models. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110644

Vancouver

Klimovich A, Kvetkina A, Deryavko Y, Priymenko N, Popkova D, Bystritskaya E, et al. TRPV1 Blocker, Peptide HCRG21 from Sea Anemone Heteractis magnifica, Exhibits Effectiveness in Psoriasis and Dermatitis in In Vivo Models. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110644

BibTeX
@article{Klimovich2025,
  author = {Klimovich, Anna and Kvetkina, Aleksandra and Deryavko, Yulia and Priymenko, Nadezhda and Popkova, Daria and Bystritskaya, Evgenia and Isaeva, Marina and Gladkikh, Irina and Sintsova, Oksana and Leychenko, Elena},
  title = {TRPV1 Blocker, Peptide HCRG21 from Sea Anemone Heteractis magnifica, Exhibits Effectiveness in Psoriasis and Dermatitis in In Vivo Models},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262110644}
}
Kostenlos starten →